Apr 11,2023

PathAI to Present on AI-based Models to Advance Tumor Analysis and Oncology Drug Development at American Association for Cancer Research Annual Meeting 2023

PathAI, a leading provider of AI-powered pathology tools to advance precision medicine, today announced their recent research will be presented at the American Association for Cancer Research Annual Meeting 2023, which will be held in Orlando, FL from April 14-19, 2023. PathAI will share three posters that highlight uses and advantages of AI-based methods to identify and examine non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC) specimens. Additionally, PathAI collaborated with Genentech, a member of the Roche Group, on two submissions, an oral presentation on H&E-based digital pathology biomarkers in metastatic NSCLC, and a poster presentation on digital PD-L1 tumor cell scoring in NSCLC.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Apr 10,2023

ChatGPT has Potential to Help Cirrhosis, Liver Cancer Patients

A new study by Cedars-Sinai investigators describes how ChatGPT, an artificial intelligence (AI) chatbot, may help improve health outcomes for patients with cirrhosis and liver cancer by providing easy-to-understand information about basic knowledge, lifestyle and treatments for these conditions. The findings, published in the peer-reviewed journal Clinical and Molecular Hepatology, highlights the AI system’s potential to play a role in clinical practice. Patients diagnosed with liver cancer and cirrhosis, an end-stage liver disease that is also a major risk factor for the most common form of liver cancer, often require extensive treatment that can be complex and challenging to manage. Personalized education AI models could help increase patient knowledge and education, noted Alexander Kuo, MD, medical director of Liver Transplantation Medicine at Cedars-Sinai and co-corresponding author of the study.

CLINICAL STUDY

#ai/software

#chatbot

View Analyst & Ambassador Comments
Go to original news
Apr 06,2023

Baptist Health Miami Cancer Institute expands partnership with COTA

Baptist Health Innovations and COTA’s collaboration has added new technology for cancer care. This partnership provides physicians with real-world evidence (RWE) for cancer care, allowing them to look at data from many levels and analyze the cost-effectiveness of healthcare services. Miami Cancer Institute used COTA’s analysis of RWE to change its testing policy for breast cancer gene mutations.

COLLABORATION PARTNERSHIP

#institution

#rwe

View Analyst & Ambassador Comments
Go to original news
Apr 04,2023

PathAI Announces PathExplore, an AI-powered Pathology Panel to Unlock Untapped Insights from the Tumor Microenvironment

PathAI, a global leader in AI-powered pathology, today announced the launch of PathExplore™, the world’s first structured, standardized and scalable panel of human interpretable features (HIFs) offering unprecedented resolution of the tumor microenvironment (TME) from H&E whole-slide images. Powered by artificial intelligence, PathExplore spatially characterizes the TME with single-cell resolution, giving oncology drug developers the ability to unlock insights to inform the next phase of targeted oncology drug development.

PRODUCT

#ai/software

View Analyst & Ambassador Comments
Go to original news
Apr 03,2023

CancerIQ’s NCoBC 2023 Recap: How Breast Centers are Connecting Risk Assessment and Preventive Care

The National Consortium of Breast Centers Annual Interdisciplinary Breast Center Conference (NCoBC) is the premiere annual event for breast health professionals. A poster presentation highlighting new data from Adventist Health showed that the health system’s partnerships with CancerIQ and Myriad Genetics helped identify more high-risk patients in breast imaging settings. The retrospective study was based on data from one Adventist Health breast imaging site in Hawaii that used CancerIQ for comprehensive cancer risk assessment and preventive care plan management, and partnered with Myriad Genetics for patient education and genetic testing.

PRODUCT
View Analyst & Ambassador Comments
Go to original news
Apr 03,2023

Tempus Announces Second Sequencing Collaboration with Lilly to Expand Patient Access to Genomic Testing

Tempus, a leader in artificial intelligence and precision medicine, today announced a new collaboration sponsored by Eli Lilly and Company designed to expand access to genomic testing for eligible patients who have advanced or metastatic medullary thyroid cancer or advanced or metastatic non-medullary thyroid cancer. This collaboration offers Tempus’ molecular profiling offerings at no cost while simultaneously working with physicians to support them in providing data-driven treatment to their patients with the use of broad-panel genomic testing. This collaboration builds upon the initial partnership with Lilly announced in June 2022 focused on providing broader access to genomic testing for patients with advanced/metastatic non-small cell lung cancer.

COLLABORATION PARTNERSHIP

#product & service

#ai/software

#rwd

View Analyst & Ambassador Comments
Go to original news
Apr 02,2023

M2GEN & ORIEN at AACR 2023 Highlighting Discoveries Using Avatar Data

M2GEN, an oncology-focused health informatics solutions company, today announced its participation as a presenter, exhibitor, and research partner at the American Association for Cancer Research (AACR) Annual Meeting April 14-19, in Orlando, Florida. Eight poster presentations and one oral presentation will be presented at AACR, utilizing the lifetime patient-consented longitudinal clinicogenomic data from M2GEN's Oncology Research Information Exchange Network® (ORIEN) Avatar program, showcasing the collaboration of scientists across ORIEN, M2GEN, and other leading cancer centers across the nation.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Apr 02,2023

Absci Partners with M2GEN to Accelerate Drug Creation for Oncology

Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, and M2GEN, an oncology bioinformatics company with the most advanced lifetime-consented clinicogenomics data to accelerate discovery research, today announced a partnership to create new cancer medicines and bring them to market at unprecedented speed. Absci’s generative AI drug creation platform will tap into M2GEN’s clinical and molecular data set, ORIEN AVATAR® (AVATAR), to accelerate the creation of therapeutics for a range of malignancies and patient profiles, bringing AI drug creation to the fight against cancer. This partnership brings together AI drug creation technology and oncology bioinformatics to potentially reduce the time and cost to create better cancer treatments.

COLLABORATION PARTNERSHIP

#r&d

#ai/software

#rwd

View Analyst & Ambassador Comments
Go to original news
Mar 30,2023

Kaiku Health Digital Patient Monitoring enhances the early detection of evolving peripheral sensory neuropathy and reduces phone call burden

Oulu University Hospital, Vaasa Central Hospital and Elekta (Kaiku Health) have published the first scientific results from a study investigating the use of digital patient monitoring for colorectal cancer (CRC) patients receiving oxaliplatin-based chemotherapy. The study was designed to investigate whether digital patient monitoring could enhance and personalize symptom management as well as improve patient follow-up and empowerment while simplifying care teams’ workflow. In this multicenter trial, Kaiku Health digital patient monitoring platform was provided for CRC patients with advanced disease receiving oxaliplatin-based chemotherapy in the first- or second-line setting or as an adjuvant treatment. Patients received weekly reminders to report on their symptoms through the platform and the care team was notified in the presence of more severe symptoms or unfavorable development. The results generated in the prospective study were compared to a retrospective cohort curated from the patient records at the same institutes. A specific adverse effect of interest in the study was peripheral sensory neuropathy. In the study, earlier detection of peripheral sensory neuropathy (p = 1e?5), did not translate to earlier dose reduction, delays, or unplanned therapy termination compared to the retrospective cohort. In addition, the feasibility of the ePRO follow-up was found to be good with 98% of the patients reporting that the use of the platform was very easy or easy to use.

CLINICAL STUDY

#rpm

View Analyst & Ambassador Comments
Go to original news
Mar 30,2023

Varian Users Achieve Key Milestones in Adoption of HyperSight Imaging Solution

Varian, a Siemens Healthineers company, today shared two key milestones as its users continue to adopt the new HyperSight™ imaging solution on the Ethos™ and Halcyon® radiotherapy systems. Firstly, Varian has completed the first commercial installation in the world of a new Halcyon system equipped with HyperSight at Huntsman Cancer Institute. Additionally, Health Canada has granted Investigational Testing Authorization for a clinical study at Nova Scotia Health evaluating potential benefits of HyperSight on an Ethos system.

PRODUCT

#ai/software

View Analyst & Ambassador Comments
Go to original news
Subscribe to ONCOLOGY